The antidepressant-like effects of the water extract of Panax ginseng and Polygala tenuifolia are mediated via the BDNF-TrkB signaling pathway and neurogenesis in the hippocampus.
Animals
Antidepressive Agents
/ isolation & purification
Behavior, Animal
/ drug effects
Brain-Derived Neurotrophic Factor
/ metabolism
Depression
/ metabolism
Disease Models, Animal
Exploratory Behavior
/ drug effects
Food Preferences
/ drug effects
Hippocampus
/ drug effects
Male
Motor Activity
/ drug effects
Neurogenesis
/ drug effects
Panax
/ chemistry
Plant Extracts
/ isolation & purification
Polygala
/ chemistry
Rats, Sprague-Dawley
Receptor, trkB
/ metabolism
Signal Transduction
Solvents
/ chemistry
Water
/ chemistry
BDNF
CUMS
Depression
Neurogenesis
SY
Journal
Journal of ethnopharmacology
ISSN: 1872-7573
Titre abrégé: J Ethnopharmacol
Pays: Ireland
ID NLM: 7903310
Informations de publication
Date de publication:
01 Mar 2021
01 Mar 2021
Historique:
received:
20
05
2020
revised:
04
10
2020
accepted:
23
11
2020
pubmed:
29
11
2020
medline:
3
3
2021
entrez:
28
11
2020
Statut:
ppublish
Résumé
The water extract of Panax ginseng (GT) and Polygala tenuifolia (YT), the main constituents of the commonly used kai-xin-san formula of traditional Chinese medicine, represents SY. It possesses strong neuroprotective effects. Using behavioural tests, we have previously established that the SY formulation exerts superior antidepressant activity than that of GT or YT. To elucidate the impact of SY treatment on chronic unpredictable mild stress (CUMS)-induced depressive-like behaviours and the prospective mechanism related to hippocampal neurogenesis and the BDNF signaling pathway. We exposed Sprague-Dawley rats (male; 180-200 g) to CUMS for 35 days. The rats in the experimental treatment groups were daily treated with either fluoxetine (10 mg kg s: The results of SPT, NSFT, FST, and TST in CUMS-exposed rats confirmed the antidepressant actions of SY. Additionally, SY treatment induced the BDNF signaling pathway and reversed the hippocampal neurogenesis caused by CUMS. Moreover, we found that the TrkB antagonist K252a blocked SY effects on behavioural improvement, inhibited the incremental effects of SY on hippocampal neurogenesis, and eliminated the impact of SY on BDNF-TrkB signaling activation. Thus, the impact of SY treatment on BDNF signaling molecules (pAkt, pERK1/2, and pCREB) were significantly inhibited by K252a. This study showed that SY acted as an antidepressant in rats exhibiting CUMS-induced depressive-like behaviours, and was facilitated by promoting hippocampal neurogenesis and the BDNF signaling pathway activation. Thus, SY could act as a potential novel supplement or adjuvant to prevent or treat clinical depressive disorders.
Identifiants
pubmed: 33248184
pii: S0378-8741(20)33513-3
doi: 10.1016/j.jep.2020.113625
pii:
doi:
Substances chimiques
Antidepressive Agents
0
Bdnf protein, rat
0
Brain-Derived Neurotrophic Factor
0
Plant Extracts
0
Solvents
0
Water
059QF0KO0R
Ntrk2 protein, rat
EC 2.7.10.1
Receptor, trkB
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113625Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.